Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors), By Region, And Segment Forecasts, 2019 - 2025

Industry Insights

The global breast cancer drugs market size was valued at USD 16.98 billion in 2017 and is expected to register at a CAGR of 10.7% over the forecast period. Rising prevalence of the disease along with emerging novel therapies are some of the major factors likely to drive the market. Early detection of breast cancer is a key to effective management of the disease.

Early detection can lead to desired outcomes including increased survival rate, number of treatment options, and improved quality of life. According to an article 2018 Research Fast Facts published by Susan G. Komen, early detection and regular screening with mammography can lower the death rate by 30%.

According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age.

High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially, whereas a steep decrease was noted for F. Hoffmann-La Roche Ltd, Novartis, AstraZeneca, and Bristol-Myers Squibb Company.

Type Insights

HER2 inhibitors is identified as the most lucrative segment of the breast cancer drugs market. Growing incidence of HER2 positive breast cancer is the major factor attributed to the growth of this segment. According to an article published by F. Hoffman La Roche Ltd in 2013, it was estimated that approximately one in five women diagnosed with breast tumor would have HER2 positive cancer. Moreover, rapidly growing demand from emerging markets such as Asia Pacific and Latin America, is expected to further drive the growth during the forecast period.

CDK 4/6 inhibitor is expected to be the fastest growing segment over the forecast period. These drugs are expected to improve the survival rate in patients with metastatic breast cancer. Moreover, commercialization of novel drugs, such as Kisqali by Novartis AG and Verzenio by Eli Lilly and Company is expected to propel growth of the segment in the forthcoming years.

Regional Insights

Increasing awareness and presence of established R&D infrastructure are among the key factors contributing to growth of the market in North America. Moreover, presence of key players such as Pfizer, Inc.; Merck & Co., Inc.; Celgene Corporation; and AbbVie, Inc. in the region is expected to drive the growth. Rising awareness about the benefits of early detection of cancer has driven the U.S.-based companies to make considerable investments in the development of targeted therapy drugs.

Asia Pacific is anticipated to expand at the fastest CAGR of 11.9% during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing and R&D in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease is anticipated to propel the regional growth. For instance, Wacoal Corp. runs the Pink Ribbon Fitting Campaign and donates funds to Japan Society of Breast Health, J. POSH, and Japan Cancer Society (Smile Fund) on behalf of customers.

Breast Cancer Drugs Market Share Insights

Some of the major market players include F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.

New product developments, acquisitions, collaborations, and regional expansions are some of the key strategic initiatives undertaken by major players to maintain stability in the market. For instance, in March 2017, Kisqali received the Food and Drug Administration (FDA) approved HR+/HER2 as the first-line treatment for metastatic breast cancer in combination with an aromatase inhibitor. Kisqali is the only CDK 4/6 inhibitor approved for treatment of advanced stages of this disease in U.S.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global breast cancer drugs market report on the basis of type and region:

• Type Outlook (Revenue, USD Million, 2014 - 2025)

  • HER2 Inhibitors

  • Mitotic Inhibitors

  • Anti-metabolites

  • Aromatase Inhibitors

  • CDK 4/6 Inhibitors

  • Hormonal Receptor

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • India

    • Japan

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa